> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly Reports Miss on Alzheimer’s Study
- URL: https://www.fdaweb.com/lilly-reports-miss-on-alzheimers-study/
- Published: 2020-02-10T12:00:00.000Z
- Updated: 2026-09-14T16:02:28.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146053

Eli Lilly says it does not plan to pursue an NDA submission for solanezumab for treating patients with dominantly inherited Alzheimer’s disease, also known as autosomal dominant Alzheimer’s disease, based on recent clinical trial results. The company says that an analysis performed by Washington University School of Medicine in the Dominantly Inherited Alzheimer Network Trials Unit Study showed that solanezumab did not meet the primary endpoint. The researchers are evaluating results for secondary endpoints and biomarkers. Results will be presented at the Advances in Alzheimer’s and Parkinson's Therapies Focus Meeting in April. A separate trial of solanezumab, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study, is not impacted by the recent data, the [company says](https://investor.lilly.com/news-releases/news-release-details/lilly-announces-topline-results-solanezumab-dominantly-inherited?ref=fdaweb.com).  

Solanezumab is an investigational anti-amyloid monoclonal antibody being studied in preclinical Alzheimer’s disease. The A4 Study is a clinical trial testing solanezumab in older individuals who have evidence of amyloid in their brains, but do not show symptoms of memory impairment, Lilly says.